Remsima® (infliximab), is the world’s first biosimilar monoclonal antibody(mAb) for the treatment of autoimmune diseases developed by Celltrion. Remsima® is developed into dual formulation of intravenous and subcutaneous.
Remsima® 120mg solution for injection in pre-filled pen
Remsima® 120mg solution for injection in
pre-filled syringe with needle guard
1. Remsima® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/Remsima®-epar-product-information_en.pdf Accessed 4 Sep 2020.
2. Jin, Jing-Fen et al. “The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. ” Patient preference and adherence vol. 9 923-42. 2 Jul. 2015, doi:10.2147/PPA.S87271
SC, subcutaneous; AS, ankylosing spondylitis; CD, Crohn's disease; EMA, European Medicines Agency; PsA, psoriatic arthritis; PsO, plaque psoriasis; RA, rheumatoid arthritis; UC, ulcerative colitis
The link you have selected will take you to a third-party website. It is not under the review or control of Celltrion Healthcare and the company does not review or control the contents. The company does not endorse the content, its accuracy or any practices and standards contained in the website.
Please confirm if you wish to follow the link.